ArchPoint Investors’s Novavax NVAX Stock Holding History

ArchPoint Investors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5,500	Closed	-$596K	–	122
2020 Q3	$596K	Buy	+5,500	New	+$670K	0.19%	64

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ArchPoint Investors's NVAX Position: Q4 2020 in Review

ArchPoint Investors sold out of Novavax (NVAX) in Q4 2020, closing a stake of 5,500 shares — an estimated $596K sold.

ArchPoint Investors first reported a position in NVAX in Q3 2020 and held it in 1 quarter. The position peaked at $596K in Q3 2020. 347 funds tracked by Wall St. Rank hold NVAX as of Q4 2020.

ArchPoint Investors reported no remaining Novavax position as of Q4 2020 after selling out during the quarter.
ArchPoint Investors sold 5,500 Novavax shares in Q4 2020, an estimated $596K.
ArchPoint Investors first reported a position in Novavax in Q3 2020 and held it in 1 quarter.
ArchPoint Investors's Novavax position peaked at $596K in Q3 2020.
347 funds tracked by Wall St. Rank held Novavax as of Q4 2020.

Based on ArchPoint Investors's 13F filing for Q4 2020, filed 12 Feb 2021.